In addition, AURKA overexpression is linked to acquired resistance to EGFR-TKI via epithelial-mesenchymal transition (EMT), and AURKA inhibitor alisertib has shown to restore NSCLC cells sensitivity to EGFR-TKI and to partially reverse EMT (58). Here, EGFR is linked to non-small cell lung carcinoma.